Analysts forecast that Gilead Sciences, Inc. (NASDAQ:GILD) will report $5.52 billion in sales for the current quarter, according to Zacks Investment Research. Seven analysts have issued estimates for Gilead Sciences’ earnings. The highest sales estimate is $5.71 billion and the lowest is $5.43 billion. Gilead Sciences reported sales of $5.65 billion during the same quarter last year, which indicates a negative year over year growth rate of 2.3%. The company is expected to issue its next quarterly earnings results on Wednesday, July 24th.
According to Zacks, analysts expect that Gilead Sciences will report full-year sales of $22.07 billion for the current fiscal year, with estimates ranging from $21.63 billion to $22.69 billion. For the next year, analysts expect that the business will report sales of $22.70 billion, with estimates ranging from $21.81 billion to $23.60 billion. Zacks’ sales averages are an average based on a survey of sell-side research firms that follow Gilead Sciences.
Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Thursday, May 2nd. The biopharmaceutical company reported $1.76 EPS for the quarter, topping analysts’ consensus estimates of $1.53 by $0.23. Gilead Sciences had a net margin of 26.40% and a return on equity of 37.98%. The business had revenue of $5.28 billion during the quarter, compared to the consensus estimate of $5.29 billion. During the same quarter in the previous year, the firm posted $1.48 EPS. The firm’s revenue was up 3.8% on a year-over-year basis.
Several equities analysts recently commented on GILD shares. Zacks Investment Research upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $69.00 price target on the stock in a report on Tuesday, April 23rd. BidaskClub cut shares of Gilead Sciences from a “buy” rating to a “hold” rating in a research report on Wednesday, June 5th. Oppenheimer set a $85.00 price target on shares of Gilead Sciences and gave the stock a “buy” rating in a report on Tuesday, March 19th. Maxim Group reiterated a “buy” rating and issued a $84.00 price objective on shares of Gilead Sciences in a research note on Friday, March 29th. Finally, JPMorgan Chase & Co. restated a “buy” rating and set a $87.00 price target on shares of Gilead Sciences in a research report on Tuesday, May 7th. One analyst has rated the stock with a sell rating, nine have issued a hold rating and fifteen have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $79.54.
GILD stock traded up $0.21 during mid-day trading on Friday, hitting $66.99. The company had a trading volume of 3,849,939 shares, compared to its average volume of 7,101,486. The stock has a market cap of $84.27 billion, a P/E ratio of 10.89, a PEG ratio of 0.63 and a beta of 1.10. Gilead Sciences has a 12-month low of $60.32 and a 12-month high of $79.61. The company has a quick ratio of 3.53, a current ratio of 3.62 and a debt-to-equity ratio of 1.09.
The firm also recently declared a quarterly dividend, which will be paid on Thursday, June 27th. Shareholders of record on Friday, June 14th will be issued a $0.63 dividend. The ex-dividend date of this dividend is Thursday, June 13th. This represents a $2.52 annualized dividend and a dividend yield of 3.76%. Gilead Sciences’s dividend payout ratio (DPR) is currently 40.98%.
In other Gilead Sciences news, Director Richard James Whitley sold 9,534 shares of the business’s stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $65.48, for a total transaction of $624,286.32. Following the completion of the sale, the director now directly owns 34,669 shares of the company’s stock, valued at approximately $2,270,126.12. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director John Francis Cogan sold 2,868 shares of the company’s stock in a transaction that occurred on Wednesday, May 1st. The shares were sold at an average price of $64.89, for a total value of $186,104.52. Following the completion of the transaction, the director now directly owns 57,728 shares of the company’s stock, valued at $3,745,969.92. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 28,602 shares of company stock valued at $1,863,445. Corporate insiders own 0.20% of the company’s stock.
Hedge funds have recently modified their holdings of the stock. Athena Capital Advisors LLC purchased a new stake in Gilead Sciences in the fourth quarter worth about $27,000. Capital Financial Planning LLC bought a new stake in shares of Gilead Sciences during the 4th quarter valued at $27,000. Creative Financial Designs Inc. ADV grew its position in shares of Gilead Sciences by 55.9% during the 1st quarter. Creative Financial Designs Inc. ADV now owns 460 shares of the biopharmaceutical company’s stock valued at $30,000 after acquiring an additional 165 shares during the period. Claybrook Capital LLC purchased a new position in shares of Gilead Sciences during the 4th quarter valued at $32,000. Finally, Trustcore Financial Services LLC purchased a new position in shares of Gilead Sciences during the 1st quarter valued at $34,000. Institutional investors own 78.78% of the company’s stock.
Gilead Sciences Company Profile
Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.
See Also: What are Institutional Investors?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.